Welcome to our dedicated page for Scpharmaceutical news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on Scpharmaceutical stock.
scPharmaceuticals Inc. (SCPH) delivers innovative subcutaneous therapies that transform intravenous treatment protocols for heart failure and related conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely announcements about FUROSCIX advancements, partnership agreements, and research breakthroughs. Our curated collection includes earnings reports, FDA submissions, and analyses of the company’s unique drug-device integration strategy in cardiorenal care.
Discover how SCPH’s subcutaneous delivery platform addresses healthcare cost reduction through outpatient treatment solutions. Stay informed about trial results, manufacturing updates, and market expansion efforts shaping this clinical-stage biopharma’s trajectory.
Bookmark this page for consolidated access to verified SCPH developments, carefully sourced to support informed decision-making in dynamic pharmaceutical markets.
scPharmaceuticals (Nasdaq: SCPH) announced that its CEO, John Tucker, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The presentation will occur at 5:00 PM ET, with Tucker also engaging in meetings with investors throughout the day. The webcast of the presentation will be accessible via the company’s Investor Relations section on its website.
scPharmaceuticals (SCPH) reported first quarter 2024 financial results, with notable achievements in FUROSCIX®. The company generated $6.1 million in net FUROSCIX revenue, despite a 10% dose impact from the Change Healthcare cyberattack. There was a 28% increase in total doses written and a 15% rise in doses filled compared to Q4 2023. The company ended Q1 with $58.4 million in cash and equivalents. Key developments include enrolling the first patient in a PK study for an 80mg/1mL auto-injector and submitting a sNDA to expand FUROSCIX's indication to NYHA Class IV heart failure patients, with a PDUFA date set for August 2024. However, scPharmaceuticals reported a net loss of $14.1 million for the quarter, with increased R&D and SG&A expenses.
scPharmaceuticals (Nasdaq: SCPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ World Headquarters in New York on May 20, 2024, at 11:00AM ET.
John Tucker, President & CEO, will present and meet with investors. The company's focus is on developing and commercializing products to optimize the delivery of infused therapies, improve patient care, and reduce healthcare costs. The presentation will be webcast and available in the Investor Relations section of the company's website.
scPharmaceuticals Inc. will announce its first-quarter 2024 financial results on Tuesday, May 14, 2024. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a business update. Participants can access the call by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with the conference code 89054. The webcast and replay will be available on the Investor Relations section of the company's website.
FAQ
What is the current stock price of Scpharmaceutical (SCPH)?
What is the market cap of Scpharmaceutical (SCPH)?
